Skip to main content
Premium Trial:

Request an Annual Quote

Antisel to Distribute Premaitha's NIPT in Greece

NEW YORK (GenomeWeb) – Premaitha Health today said that Antisel will distribute the firm's Iona non-invasive prenatal test to clinical laboratories in Greece.

The Manchester, UK-based firm said that labs in Greece currently have to send their samples to central labs in the US and China for NIPT screening. The agreement with Antisel, which is based Athens, Greece, will provide these labs with local NIPT screening, allowing them "to take advantage of the test's time to result of just three days," Premaitha said in a statement.

The Iona test, which is CE marked, uses next-generation sequencing technology to estimate the risk of a fetus having Down's syndrome, Edwards' syndrome, and Patau's syndrome by analyzing cell-free fetal DNA from a sample of maternal blood. It also has a higher detection rate and lower false-positive rate than the current combined screening test available, the firm added.

Terms of the agreement were not disclosed.